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Abstract
First-generation cephalosporins have been advocated to replace vancomycin in the first-line antibiotic
treatment for continuous ambulatory peritoneal dialysis (CAPD) peritonitis. The aim of this study is
to evaluate the effectiveness of a first- or second-generation cephalosporin (CI/II)-based regime
and its impact on methicillin-resistant Staphylococcus peritonitis (MRSP) over a 5-year period in a
regional hospital, where vancomycin was reserved as the second-line antibiotic. From 1995 to
1999, among the 541 cases of pyogenic bacterial peritonitis, CI/II plus tobramycin (C+T) was
prescribed as the initial antibiotics in 333 cases, and vancomycin with an aminoglycoside (V+A)
was prescribed in 103 cases. The primary response rates were 70.2% for C+T and 76.7% for V+A
(p = n.s.) and the overall response rates (including subsequent change of antibiotics) were 89.8%
and 84.5% respectively (p = n.s.). In the two groups, 12% and 11.7% of peritonitis were caused by
MRS (p = n.s.). There was no significant change of primary response and overall response rates to
C+T over the 5-year period. The use of CI/II was not associated with an increased relative risk for
subsequent development of MRS infection. We concluded that CI/II together with an tobramycin is
an effective first-line antibiotic treatment with good overall response rate.
Key words: Antibiotic, Continuous ambulatory peritoneal dialysis (CAPD) peritonitis, Cephalosporin,
Vancomycin.
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INTRODUCTION
With the emergence of vancomycin-resistant enterococci
(VRE), first-generation cephalosporin was recommended
in 1996 by the Advisory Committee on Peritonitis
Management of the International Society for Peritoneal
Dialysis to replace vancomycin in the first-line antibiotic
regime for continuous ambulatory peritoneal dialysis
(CAPD) peritonitis (1). However, this recommendation
is controversial because of the high prevalence of
methicillin-resistant staphylococcus peritonitis (MRSP).
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normalization of effluent WCC, whichever was longer.
Treatment was changed if effluent culture results
indicated that the antibiotic used was inappropriate or if
response was poor to the prescribed antibiotics.
Rifampicin was used only in relapsing staphylococcal
peritonitis. Primary response was defined as complete
resolution of signs, symptoms and normalization of
dialysate effluent WCC without change of antibiotics.
Primary success was defined as primary response without
subsequent relapse, which was defined as another episode
of peritonitis caused by the same bacteria occurring
within 14 days after the last dose of antibiotics. Overall
response was defined as complete resolution of signs,
symptoms and normalization of dialysate effluent WCC
with or without change of antibiotics. Overall success
was defined as overall response without subsequent
relapse. Requirement of cessation of peritoneal dialysis,
whether temporary or permanent, or death related to
peritonitis was defined as treatment failure.
For the purpose of the study, both cefazolin and
cefuroxime based regimens were grouped together.
Treatment I was defined as either cefazolin or C+T.
Treatment II was defined as V+A. Response rates
between treatment I and II were compared with chi-
square statistics. Other antibiotic combinations were not
analyzed because of the small number.
To study the effect of using CI/II and other penicillinase-
resistant antibiotics on the emergence of MRS infections,
records were screened for 1 year before and 2 years after
the peritonitis episode with regard to the use of CI/II or
cloxacillin and the occurrence of MRS infection 12
months before the peritonitis episode and 24 months
afterwards. Nasal Staphylococcus aureus carriage was
not routinely screened in the study period. Logistic
regression was used to study the relative risk of prior
CI/II or cloxacillin prescription on the emergence of
MRSP and the use of treatment I on subsequent MRS
infections for the following 2 years.
RESULTS
Within the 5-year period from 1995 to 1999, there were
633 episodes of peritonitis occurring in a total of 12538
patient-months. There were 38 episodes of fungal
peritonitis, five episodes of tuberculous peritonitis and
49 episodes of relapsed peritonitis. There were 541 cases
of non-relapsing, non-fungal, and non-tuberculous
pyogenic bacterial peritonitis recruited into this study.
The pattern of causative organisms was shown in table 1
and the pattern of antibiotics prescription was shown in
table 2. There were five episodes with antibiotic record
not available, mainly because they were treated in other
hospitals. The overall response rate was 87.6%. There
Such a regime without vancomycin may result in poorer
outcome of peritonitis. There were few reports of clinical
results from this revised treatment strategy.
In our center, vancomycin has never been used as a first-
line antibiotic for CAPD peritonitis treatment. Before
1995, ofloxacin was used as the first-line antibiotic. From
1995 onwards, the first-line antibiotics were a combination
of a first- or second-generation cephalosporin (CI/II) and
tobramycin. Vancomycin was only used when there was
no satisfactory response to first-line antibiotics or as the
initial antibiotic for severe peritonitis. The aim of this
study is to evaluate the effectiveness of such a treatment
strategy and its impact on the emergence of MRS
infections.
PATIENTS AND METHODS
We retrospectively analyzed data of all episodes of non-
tuberculous pyogenic bacterial peritonitis in CAPD
patients under the care of the Renal Unit at Tung Wah
Hospital, Hong Kong from 1 January 1995 to 31
December 1999. Diagnosis of peritonitis was based on
abdominal pain and turbid effluent fluid with or without
fever. Peritoneal effluent fluid white blood cell count
(WCC) had to be over 100µL with neutrophils
predominance. Bacterial culture and microscopy of
peritoneal effluent was sent before antibiotics were
administered. Methicillin sensitivity was tested for all
Staphylococcal organisms. One CI/II (cephalexin,
cefazolin, or cefuroxime) sensitivity was usually reported
together with methicillin sensitivity. Tuberculous, fungal
and relapsing peritonitis were excluded in this study.
During this period, various initial antibiotic combinations
had been administered. The standard first-line antibiotics
were either cefazolin or cefuroxime plus tobramycin
(C+T). The dosage for continuous cefazolin was 1 gm
intraperitoneally (i.p.) loading over a 6 to 8 hours dwell
and 250 mg/L maintenance, cefuroxime 1.5 gm i.p.
loading and 250 mg/L maintenance, and tobramycin
16 mg i.p. loading and 4 to 8 mg/L maintenance. An
intermittent regime was also used for cefazolin and
tobramycin in some patients, with a dosage of cefazolin
1 gm i.p. and tobramycin 40 mg i.p. once per day. A
vancomycin and amikacin (V+A) combination was used
as initial therapy for severe peritonitis and as second-
line antibiotics for cases not responding to first-line
antibiotics after 3 days. Severity of peritonitis was
determined by attending doctors on clinical grounds like
severe abdominal pain and high fever but not on WCC
level. The dosage for amikacin was 50 mg i.p. loading
and 12.5 mg/L maintenance and vancomycin 1 gm for
loading and 25 mg/L for maintenance. Intermittent
vancomycin was not used. Treatment duration was
usually 2 weeks or for at least 7 more days after
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were 24 cases of subsequent relapse, making the overall
success rate 83.2%. Nineteen patients died (3.5%) and
seven patients had to be transferred to permanent
hemodialysis (HD). Forty-one patients returned back to
CAPD after a period of temporary HD. Among the 536
episodes with known antibiotics records, treatment I was
prescribed as the initial antibiotics in 333 episodes and
treatment II in 103 episodes. There were a total of 201
episodes (37.5%) given vancomycin whether as the initial
or subsequent antibiotic. Among episodes given
treatment I as the initial antibiotics, vancomycin was
subsequently prescribed in 65 episodes (19.5%).
The primary response rates of treatment I and II were
70.2% and 76.7% respectively (p = n.s.) and the primary
success rates were 66.1% and 73.8% respectively (p =
n.s.). There was no statistical significance in the relapse
rate between these two regimes (6% vs 5.5%, p = n.s.).
The respective overall success rates including subsequent
change of antibiotics were 85% vs 79.6%, (p = n.s.) and
the overall response rates were 89.8% vs 84.5% (p =
n.s.). There was no significant difference in outcome
between cefazolin based (Treatment IA) and cefuroxime
based (Treatment IB) treatment regimes (primary
response rates for treatment IA and IB were 68.5% and
71.2% respectively, p = n.s.). There was no significant
change of primary response rate and overall response
rate to treatment I over the 5 years period (primary
success rates were 71%, 66.7%, 73.3%, 69.2%, 69.5%,
and overall success rates were 87.1%, 90.2%, 93%,
88.5%, 89% for 1995 to 1999 respectively, Fig. 1).
Among the 81 episodes of S. aureus peritonitis, 20
episodes (24.7%) were due to methicillin-resistant S.
aureus (MRSA), and 47 (43.9%) of the 107 episodes of
coagulase negative Staphylococcus (CNS) peritonitis
were methicillin-resistant (MRCNS). The total number
of MRSP was 35.7% of all Staphylococcal peritonitis,
and 12.4% of all pyogenic non-relapsing peritonitis. The
incidence of MRSA and MRCNS did not differ
significantly between episodes given treatment I and
treatment II (2.7% vs 3.9% for MRSA and 9.3% vs 7.8%
for MRCNS respectively). The primary response rate of
methicillin sensitive S. aureus (MSSA) to treatment I
was 61.1% and of MRSA was 33.3% (p = n.s.), and of
methicillin sensitive coagulase negative Staphylococcus
(MSCNS) and MRCNS was 87.8% and 61.2% (p =
0.002 by chi-square). The primary response rates of
MSSA, MRSA, MSCNS and MRCNS to treatment II
were 80%, 75%, 83.3% and 87.5% respectively (p =
n.s.). The response rates of these organisms between the
Table 1.  Proportion of peritoneal effluent culture results among
541 non-fungal, non-tuberculous non-relapsing bacterial peritonitis
complicating CAPD from 1995 to 1999.*
Organisms %
No growth 25.3
MSSA 11.3
MRSA 3.7
MSCNS 11.1
MRCNS 8.7
Streptococcus spp. 8.5
Diphtheroid 2.2
E. Coli 8.3
Klebsiella spp. 3.7
Pseudomonas spp. 5.9
Acinetobacter spp. 3.1
Other Gram negative organisms 6.1
Other Gram positive organisms 1.1
Unknown 0.9
*The overall culture negative rate among all peritonitis, including
fungal, tuberculous and relapsing peritonitis, was 21.6%.
MSSA = methicillin sensitive S. aureus; MRSA = methicillin
resistant S. aureus; MSCNS = methicillin sensitive coagulase
negative Staphylococcus; MRCNS = methicillin resistant coagulase
negative Staphylococcus
Table 2.  Proportion of initial antibiotics prescribed among 541 non-
fungal, non-tuberculous non-relapsing bacterial peritonitis
complicating CAPD from 1995 to 1999.
Antibiotic regime %
Treatment I 61.6
Treatment II 20.9
Other CI/II combinations 1.1
Other vancomycin combinations 3.1
CIII based 6.1
Quinolones 3.7
Others 1.3
Unknown 0.9
Treatment I = cefazolin or cefuroxime plus tobramycin; Treatment
II = vancomycin plus aminoglycoside; CI/II = first- or second-
generation cephalosporins; CIII = third-generation cephalosporin
Figure 1.  Primary response rate (broken line) and overall success
rate (solid line) to intraperitoneal cefazolin/cefuroxime plus
tobramycin from 1995 to 1999.
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two treatment regimes were not statistically different.
Two out of 19 episodes of MRCNS successfully treated
with treatment I were subsequently followed by relapse,
but none of the MSCNS were complicated with relapse
(p = n.s. by Fisher exact test). Among the culture-negative
peritonitis, the primary response rates to treatment I and
II were 87.1% and 90% respectively (p = n.s.).
There was no obvious trend of increase in MRSP (Fig.
2-4). With logistic regression on all 543 patients, both
previous exposure to cloxacillin or CI/II and previous
history of MRS infections were independent risk factors
for MRS peritonitis (R.R. of cloxacillin and/or CI/II was
2.45, p = 0.0461, of previous MRS was 1.97, p = 0.0128).
However, for subsequent MRS infections, only previous
MRS infections and MRSP were independent risk factors
(R.R. = 3.23, p = 0 and R.R. = 2.52, p = 0.001
respectively) but not the use of treatment I nor previous
history of use of cloxacillin and/or CI/II.
DISCUSSION
Although first-generation cephalosporin has been
recommended to replace vancomycin in the first-line
antibiotic regime for CAPD peritonitis, there were few
available data on the efficacy of this recommendation in
the past few years during which MRS infections were
frequent. In the literature, the primary response rate of
cefazolin with an aminoglycoside varies between 60%
and 92% (2-5). The variation was largely related to the
incidence of MRS peritonitis. The primary response rate
of 70% for CI/II and tobramycin in this study was within
the reported range but this response rate cannot be
regarded as a good rate. Regimes using V+A, or (broad)-
spectrum potent antibiotics combinations including third-
or fourth-generation cephalosporins and imipenem often
achieve a cure rate of above 80%, or even up to 90% (2,
6-9). In the present study, the overall success rate of using
CI/II with tobramycin including a subsequent change of
antibiotics was around 85%, quite comparable to those
regimes using more potent, more broad-spectrum
antibiotics. This indicates that the present treatment
strategy is effective without compromising patient
outcome. The advantage of this treatment strategy is that
it minimizes the use of vancomycin and third- or fourth-
generation cephalosporins, which have been implicated
in the emergence of VRE and vancomycin-resistant
Staphylococcus, and extended spectrum beta-lactamase
Enterobacteriaceae (10-13). Vancomycin was ultimately
used in only 37.5% of all episodes in this study.
Compared to a vancomycin-based regime, it saved
around two thirds of patients from unnecessary exposure
to vancomycin. Only 65 patients (19.5%) using treatment
I required vancomycin subsequently, among which
83.1% responded to the second-line antibiotics.
In this study, the success rates of treatment I and
treatment II were very similar, which implies that their
efficacy were similar. In fact, 83% of patients who did
not respond to treatment I responded to treatment II, the
Figure 2.  Numbers of episodes of peritonitis due to MRSA and
MSSA from 1995 to 1999.
MSSA = methicillin sensitive staphylococcus aureus; MRSA =
methicillin resistant staphylococcus aureus
Figure 3.  Numbers of episodes of peritonitis due to MRCNS and
MSCNS from 1995 to 1999.
MSCNS = methicillin sensitive coagulase negative staphylococcus;
MRCNS = methicillin resistant coagulase negative staphylococcus
Figure 4.  Numbers of episodes of peritonitis due to MRS and
MSS from 1995 to 1999.
MSS = methicillin sensitive staphylococcus; MRS = methicillin
resistant staphylococcus
19
Hong Kong J Nephrol 2001;3(1):15-20. H QI, et al
vancomycin-based regime, after the switch of antibiotics.
As treatment II was mainly prescribed for severe
peritonitis, the similar response rates of treatment II
indicated that the vancomycin-based regime should be
more efficacious than the CI/II-based regime. We also
did not find significant differences in outcome between
using first- and second-generation cephalosporins.
Because cefazolin and cefuroxime sensitivity had not
been routinely tested with every staphylococcal
organism, specific data concerning their resistance was
not available, but their sensitivity in general closely
resembled that of methicillin. The opinion of the
microbiologists was that methicillin sensitivity could
represent first-generation cephalosporin sensitivity for
staphylococcal infection. The choice between cefazolin
and cefuroxime in our center was mainly related to the
availability and price of these first- or second-generation
cephalosporins, both of which had fluctuated over the
study period.
The incidence of MRSA was only 11.3% of all pyogenic
bacterial peritonitis, and 24.7% of all staphylococcus
aureus peritonitis. The incidence of MRSA varies widely
among different dialysis centers. The response rate of
CI/II-based regimes may be expected to be lower in areas
with high incidence of MRSA peritonitis. The response
rate of MRSA to treatment I was much lower than to
treatment II, though not statistically different because of
the small number. It is worth noting that the incidence
of MRCNS was as high as 44% of all CNS peritonitis.
There was a report that MRCNS was as high as 89% of
all CNS peritonitis (14). The response rate of MRCNS
in this series was also lower with treatment I than with
treatment II, though much better compared with that of
MRSA. However, as we have adopted the policy of
changing the antibiotics routinely to vancomycin for
MRCNS peritonitis independent of its clinical response
to avoid relapse which had been observed in some
patients continuing on treatment I, the real primary
response rate should be higher than the present 61%. The
rising trend of MRCNS certainly raises considerable
worry despite that this organism is generally considered
as non-virulent (15). The response rate and the pattern
of microbiology causing CAPD peritonitis must have to
be determined in each center to adopt the most effective
treatment regime while minimizing the use of
vancomycin and broad-spectrum beta-lactam antibiotics.
One worry of using CI/II based regimes is the emergence
of MRS following frequent exposure to these antibiotics.
There was a report of a correlation between the increase
in utilization of cloxacillin and first-, second-, and third-
generation cephalosporins with the increase in MRCNS
(15). Data from the current study did not show such a
link. The occurrence of MRSP or MRS infections was
related to previous history of such infections rather than
to previous exposure to these antibiotics or the use of
the CI/II based antibiotic regimes. The incidence and
proportion of MRS (including MRSA and MRCNS) did
not show a rising or falling trend over the 5-year period
allowing us to continue to use the present treatment
strategy. However, it is of interest to note that the
incidence of MRS actually fluctuated quite a lot from
year to year. The apparently low incidence of MRSA in
the beginning of the study period was actually just a
fluctuation from the average, which was around 20% of
all staphylococcus aureus peritonitis in early 1990's in
our center.
We concluded that CI/II plus tobramycin as the initial
antibiotics with V+A as the second-line antibiotics is an
effective treatment strategy with a reasonably good
outcome. It significantly reduces unnecessary use of
vancomycin or third-generation cephalosporins. No
rising trend of MRS infections has been noticed with its
use. However, continuous monitoring of its response rate
and the incidence of MRS infections is recommended. It
must be pointed out that the present CI/II plus
aminoglycoside combination is not an ideal regime in
the sense that aminoglycoside may damage residual renal
function. A search for a regime without vancomycin and
aminoglycoside is needed, as was described in the latest
peritoneal dialysis related-peritonitis treatment
recommendation from the International Society for
Peritoneal Dialysis in 2000 (16).
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